Lovastatin is a member of Statins, which are beneficial in a lot of immunologic cardiovascular diseases and T cell-mediated autoimmune diseases. Kv1.3 channel plays important roles in the activation and proliferation of T cells, and have become attractive target for immune-related disorders. The present study was designed to examine the block effect of Lovastatin on Kv1.3 channel in human T cells, and to clarify its new immunomodulatory mechanism. We found that Lovastatin inhibited Kv1.3 currents in a concentration-and voltage-dependent manner, and the IC50 for peak, end of the pulse was 39.81 ± 5.11, 6.92 ± 0.95 μM, respectively. Lovastatin also accelerated the decay rate of current inactivation and negatively shifted the steady-state inactivation curves concentration-dependently, without affecting the activation curve. However, 30 μM Lovastatin had no apparent effect on K Ca current in human T cells. Furthermore, Lovastatin inhibited Ca 2+ influx, T cell proliferation as well as IL-2 production. The activities of NFAT1 and NF-κB p65/50 were downregulated by Lovastatin, too. At last, Mevalonate application only partially reversed the inhibition of Lovastatin on IL-2 secretion, and the siRNA against Kv1.3 also partially reduced this inhibitory effect of Lovastatin. In conclusion, Lovastatin can exert immunodulatory properties through the new mechanism of blocking Kv1.3 channel.
Lovastatin belongs to the medication family called Statins. Statins are the oral competitive inhibitors of 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, which catalyzes the conversion of HMG-CoA to L-Mevalonate, leading to the blockade of cholesterol biosynthesis. Meanwhile, L-Mevalonate is the precursor for many isoprenoid metabolites. Statins would also inhibit the biosynthesis of isoprenoid intermediates such as geranyl and farnesyl pyrophosphate, and then affect the posttranslational prenylation of several important cell-signaling proteins during immune responses [1] [2] [3] . Consequently, along with the lipid-lowering effects, Statins have been demonstrated to exert immunomodulatory properties which decrease the risk of cardiovascular events, such as ischemic heart disease 4, 5 and atrial fibrillation 6 . In recent years, more research focus on the immunomodulatory effect of Statins in inflammatory autoimmune diseases 7 . Statins have been reported to be beneficial in a lot of T cell-mediated autoimmune diseases, including experimental autoimmune encephalomyelitis 8 , type 1 diabetes 9 , inflammatory arthritis 10 , autoimmune myocarditis 11 , and autoimmune thyroiditis 12 . Furthermore, many reports suggested that Statins inhibited T cell activation by blocking the Mevalonate pathway and reducing the isoprenoid metabolites 9, 13, 14 . Particularly, Lovastatin can inhibit the prenylation and posttranslational activation of Rho GTPase, which facilitates T cell migration, and then suppresses the autoimmune damage in encephalomyelitis and retinal inflammatory disease 8, 15 . Nevertheless, the immunomodulatory mechanism of Lovastatin in the treatment of T cell-mediated inflammatory diseases which has not been clarified completely requires further study.
Recently, the Kv1.3 channel in T cells has been the novel target for the treatment of many T cell-mediated autoimmune diseases 16 . Kv1.3 channel belongs to the Shaker family, which is preferentially expresses in T cells. Along with K Ca channels, Kv1.3 channel regulates the resting membrane potential and provides sustained driving force for the Ca 2+ influx through Ca 2+ -release activated Ca 2+ (CRAC) channel in T cells. Ca 2+ influx can activate the Ca 2+ -dependent signal transcription pathway, and then induces the activation, proliferation and IL-2 secretion of T cells 17, 18 . Blocking Kv1.3 channel can inhibit the Ca 2+ influx and Ca 2+ -mediated signal pathway, and then exert inhibitory effects on T cell activation [19] [20] [21] [22] . In many autoimmune animal models such as multiple sclerosis, rheumatoid arthritis, Type I diabetes, the pathogenic T EM (effector memory T) cells were reported to significantly up-regulate Kv1.3 channel expression after activation, therefore, Kv1.3 blockers can selectively inhibit T EM cells and alleviate the immunologic damage 16, [23] [24] [25] [26] . Accordingly, Kv1.3 blockers were beneficial for T cell-mediated autoimmune diseases.
The present study was undertaken to determine if the immunomodulatory properties of Statins are mediated by blockade of Kv1.3 channel. In our study, we chose Lovastatin as a represent to validate the above hypothesis. Firstly, we found that Lovastatin concentration-and voltage-dependently blocked Kv1.3 channel in human T cells. However, Lovastatin had no effect on K Ca current, Kv1. 
Results
Lovastatin blocked Kv1.3 channel currents in human T cells. Jurkat cells were held at − 80 mV, and received the test potentials from − 80 to + 80 mV in 10 mV steps. As shown in Fig. 1A , at test potentials positive to -40 mV, Kv1.3 channel currents rapidly activated and slowly inactivated. However, with 30 μ M Lovastatin application, Kv1.3 current was much smaller and inactivated faster (Fig. 1B) . After washout, the peak current recovered nearly completely, while the current at the end of the pulse only reversed partially (Fig. 1C) . We got the similar results from peripheral blood CD4 + T cells (PBTCs, Fig. 1D -F) and CD3 + T cells (data not shown). Next, different concentrations of Lovastatin ranging from 1 to 100 μ M were applied to block the Kv1.3 channel in Jurkat cells. The current traces in the absence and presence of 10, 30 μ M Lovastatin was shown in Fig. 1G . Whereas, the quantitative analysis of concentration-dependent block effect by Lovastatin on the peak and the current at the end of the pulse was shown in Fig. 1H,I , respectively. Using the Hill equation for non-linear fitting, the IC 50 of Lovastatin on the peak current was calculated to be 39.81 ± 5.11 μ M, with the Hill coefficient 0.56 ± 0.04; and the IC 50 on the current at the end of the pulse was 6.92 ± 0.95 μ M, with the Hill coefficient 0.75 ± 0.06.
We further investigated the effects of Lovastatin on cloned human Kv1.3, Kv1.2 and Kv1.5 channels, which were transfected and expressed in HEK 293 cells. As shown in Fig. S1 , 30 μ M Lovastatin was able to inhibit 83.34 ± 2.04% of Kv1.3 channel peak currents and 93.95 ± 1.48% of currents at the pulse end. Similar blockage effects were also observed in Kv1.2 (70.71 ± 1.43%) and Kv1.5 (46.02 ± 1.43% at the peak, 83.95 ± 3.46% at the end of pulse). These results suggested that Lovastatin was a non-selective Kv1.3 blocker.
The blocking kinetics of Lovastatin on Kv1.3 channel. Next, we observed the voltage-dependent block effect of Lovastatin on Kv1.3 channel. The current density-voltage relationship curves of the peak and the current end of the pulse, before and after 30 μ M Lovastatin application, were shown in Fig. 2A ,B, respectively. Lovastatin at 30 μ M inhibited the peak and the pulse end current apparently above −40 mV when Kv1.3 channel was open. Then, we calculated the inhibition% of 30 μ M Lovastatin on the peak and the pulse end current, which was plotted as a function of the test potentials. The activation curve was present in Fig. 3C , too. From -40 mV to 0 mV, the inhibition percentage of Lovastatin on peak and pulse end current increased sharply from 8.7% and 11.0% to 36.8% and 71.1%, respectively. This voltage range was consistent with the voltage for Kv1.3 channel opening. The inhibition increased to a plateau between +10 mV and +60 mV when the channel was fully activated. This blocking character suggested that Lovastatin may bind to the open state of Kv1.3 channel.
We further investigated whether Lovastatin blocked Kv1.3 channel in the closed state. Kv1.3 currents expressed in HEK 293 cells were recorded before and after a pulse-free period of incubation with Lovastatin. Membrane potential was held at − 80 mV and Lovastatin (30 μ M) was applied to the bath without any depolarization pulses for 8 mins and then the consecutive 250 ms pulses (at + 40 mV) were given every 10 s. As shown in Fig. 2D , Lovastatin (30 μ M) did not affect the peak currents at pulse 1 (59.27 vs 55.64 pA/pF), suggesting that little Lovastatin block happened while the channel was closed. However, the onset of blockade occurred rapidly once the channel was opened (the amplitude peak current at pulse 2 was 36.35 vs. 59.27 pA/pF at pulse 1). These results indicated that Lovastatin interacted with the binding sites as the Kv1.3 channel open, with no indication of drug binding in the closed state.
In Fig. 2E , the activation curves in the absence and presence of 30 μ M Lovastatin were generated by plotting the normalized conductance with step potentials from − 80 mV to + 40 mV using Boltzman equation. Under control, the value of V 1/2 for activation was − 27.31 ± 1.90 mV and slope factor κ was 14.01 ± 1.10; with Lovastatin application, V 1/2 was calculated to be − 29.57 ± 2.30 mV and κ was 18.39 ± 1.33 (P > 0.05). To investigate the effect of Lovastatin on Kv1.3 channel inactivation, in Fig. 2F , we use a standard double-pulse protocol 19 to generate the steady-state inactivation curves. The resulting normalized current-voltage relationships were fitted using Boltzman equation to acquire the half inactivation voltage V 1/2 and κ, which were − 37.40 ± 0.65 mV and 3.36 ± 0.18 at control. Lovastatin caused a concentration-dependently negative shift of the steady-state inactivation curve. The V 1/2 was − 42.23 ± 0.99 (P < 0.05 vs. control) with 10 μ M Lovastatin, and − 47.91 ± 1.55 (P < 0.001) with 30 μ M Lovastatin. However, Lovastatin did not alter the κ value, which was 4.22 ± 0.25 at 10, 3.04 ± 0.14 at 30 μ M Lovastatin (P > 0.05). Then, the K i value of Lovastatin on inactivated-state Kv1.3 channel was calculated to be 0.95 ± 0.21 μ M in Fig. 2G . Accordingly, the effect of Lovastatin on channel inactivation was 40 times more potent than on the peak current (39.81 ± 5.11 μ M), and 7 times more potent than on the pulse end current (6.92 ± 0.95 μ M). Lovastatin may preferentially bind to the inactivated-state of Kv1.3 channel.
Furthermore, the decay phase of Kv1.3 channel current at + 40 mV was fitted using a mono-exponential equation, revealing a time constant of 312.52 ± 49.70 ms under control, and 240.26 ± 54.11 (P > 0.05), 190.67 ± 14.95 (P < 0.05), 114.29 ± 7.65 (P < 0.01), 79.79 ± 8.45 (P < 0.01) and 57.73 ± 6.41 (P < 0.001) ms at 1, 3, 10, 30, 100 μ M Lovastatin (Fig. 2H) . Lovastatin accelerated the channel decay rate in a concentration-dependent manner, similar to many other Kv1.3 open channel blockers 27, 28 .
Interaction of Lovastatin with Kv1.3 Wild-Type and Kv1.3 Mutant Channels. To characterize and identify the binding site in Kv1.3 channel that is responsible for the blocking effect of Lovastatin, we firstly performed competition experiments to investigate the interaction of Lovastatin with the known inner pore blockers tetraethyl-ammonium (TEA) and verapamil. Lovastatin (30 μ M) caused less blocking effects in the presence of internal TEA (Fig. 3B ) or external verapamil (Fig. 3C ) than expected for an independent action (Fig. 3A) . We then examined the effects of Lovastatin on Kv1.3 H399A and V417A channels, which have been demonstrated to be involved in interactions with small molecular blockers after channel opened. H399A located in the out pore region and V417A located in the S6 domain. As reported, the two mutants can produce substantial outward currents during depolarization 29 . The H399A channel was inhibited by Lovastatin (30 μ M) to an extent similar to WT (Fig. 3D) , whereas, the inhibitory effect of Lovastatin (30 μ M ) was significantly less on the V417A channel (Fig. 3E) . Figure 3F summarized the inhibitory effect of Lovastatin (30 μ M), measured as percentage inhibition of peak and pulse end currents at + 40 mV. These results suggested that Lovastatin interacted with the inner pore domain of Kv1.3 channel, and Val417 might be important for the block by Lovastatin.
Lovastatin did not block K Ca currents in human T cells. Next, we observed the block effect of Lovastatin on K Ca channel both in Jurkat T cells and PBTCs, because K Ca 2.2 is the main K Ca channel expressed in Jurkat T cells 30 , whereas K Ca 3.1 is the main K Ca channel involved in PBTCs 17 . K Ca current was elicited by a 200 ms ramp pulse ranging from − 120 mV to + 40 mV at the holding potential of − 40 mV. The representative current traces were shown in Fig. 4A ,C,E. To avoid the mixture of outward Kv currents, the slope conductance between − 120 and − 40 mV was measured by fitting the curve with linear equation. As shown in Fig. 4B ,D, 30 μ M Lovastatin did not block K Ca currents in both Jurkat cells and PBTCs in normal Ringer's solution. In Jurkat cells, the slope conductance was 0.61 ± 0.05 nS at control, and 0.65 ± 0.05 nS with Lovastatin application (n = 5, P > 0.05). In PBTCs, he slope conductance was 0.90 ± 0.14 nS at control, and 0.91 ± 0.12 nS with Lovastatin application (n = 5, P > 0.05). In Fig. 4E ,F, to increase their slope conductance, the K Ca currents were recorded in K + Ringer's solution, and similarly, 30 μ M Lovastatin exerted no block effect on K Ca channel (1.48 ± 0.19 vs. 1.48 ± 0.22 nS, P > 0.05). Consequently, our results suggested that Lovastatin had no apparent block effect on K Ca channel in human T cells. , so we further investigated the modulation effect of Lovastatin on NFAT1 and NF-κ B p65/50. In Fig. 7 , the expression of NFAT1 and phospho-NF-κ Bp65/50 was increased with stimulation by PHA + PMA (P < 0.01 for NFAT1 and p50, P < 0.05 for p65). Treatment with 10, 30 and 100 μ M Lovastatin apparently suppressed the expression level of all these three factors concentration-dependently.
Effect of
Lovastatin inhibited the proliferation and IL-2 secretion of human T cells. To investigate the functional immunosuppression effect performed by Lovastatin through inhibiting the Kv1.3 channel, we measured T cell proliferation and IL-2 production. CCK-8 kit was used to access the proliferation of anti CD3/CD28-stimulated human PBTCs, and IL-2 secretion from PHA + PMA activated Jurkat cell was measured by ELISA. In Fig. 8A,B, 3 , 10, and 30 μ M Lovastatin inhibited the T cell proliferation and IL-2 production concentration-dependently. Since Statins can exert immunomodulatory effect by blocking the isoprenoid pathway 1, 3 , we applied 1 mM Mevalonate (the intermediate of isoprenoid pathway) along with 30 μ M Lovastatin. We found that the blocking effect of Lovastatin on IL-2 secretion was partially neutralized, from 68.57% to 39.11%, which suggested that Lovastatin probably play immunomodulatory effect only partly through isoprenoid pathway. Furthermore, we knocked down Kv1.3 expression using specific Kv1.3-siRNA in Jurkat cells. The Kv1.3-siRNA transfection resulted in reduced inhibitory effect of 30 μ M Lovastatin on IL-2 production (34.27 ± 4.74% vs. NC-siRNA 65.94 ± 0.80%, P < 0.01). Simultaneously, NC-siRNA transfection did not alter the block effect of Lovastatin on IL-2 secretion (65.94 ± 0.80% vs. Jurkat cell 68.57 ± 2.20%, P > 0.05). As shown in Fig. 8E , Lovastatin also concentration-dependently reduced IL-2 secretion in Kv1.3 knockdown Jurkat cells. In conclusion, Lovastatin exerted immunomodulatory effect partly through Kv1.3 channel. 
Discussion
This is the first study to investigate the block effect of Lovastatin on Kv1.3 channel in human T cells. Our research demonstrated that Lovastatin blocked Kv1.3 channel in a concentration-and voltage-dependent manner, accelerated the decay rate of current curve and negatively shifted the steady-state inactivation curve without significant effect on K Ca channels. Different from DPO-1, Acacetin and 18β -Glycyrrhetinic acid 19, 20, 31 , Lovastatin incubation for 24 h did not change the mRNA and protein expression of Kv1.3 channel, which suggested that Lovastatin may exert its effect by direct blockade. Similar with our previous studies on other Kv1.3 blockers 19, 20, 31 , Lovastatin inhibited the Ca 2+ influx, Ca 2+ -activated transcription factors NFAT1 and NF-κ B p65/50, T cell proliferation and IL-2 production. The Mevalonate pathway is the important mechanism of Statins' immunomodulatory effect, but Mevalonate application only partially reversed the inhibition of Lovastatin on IL-2 secretion. Furthermore, siRNA against Kv1.3 channel reduced this inhibitory effect of Lovastatin on IL-2 production. Accordingly, Lovastatin can exert anti-inflammatory and immunomodulatory effect partly through Kv1.3 channel in human T cells.
Previous study has proved that Lovastatin blocked Kv1.3 channel in murine thymocytes 35 without clarifying the blocking characteristic. The IC 50 of Lovastatin for Kv1.3 current end of the pulse was 6.92 ± 0.95 μ M, and the peak plasma Lovastatin bioactivity could reach 12.3 μ M
36
. Accordingly, the effective concentration of Lovastatin for Kv1.3 blockade has good clinical relevance. We found that Lovastatin blocked Kv1.3 channel in a voltage-dependent manner, and this effect increased sharply between the voltage ranges from − 40 to 0 mV (the voltage of channel open). Moreover, Lovastatin did not produce any obvious effect until the channel was firstly opened by a depolarization pulse, which was similar to the effects of classical Kv channel pore blocker TEA 37 . But, unlike TEA, Lovastatin failed to cause the tail current crossover phenomenon, probably because Lovastatin is not a pure open-channel blocker. Furthermore, in contrast to TEA, Lovastatin concentration-dependently accelerated the decay phase of Kv1.3 channel, and negatively shifted the steady-state curves in a concentration-dependent manner, which indicated that Lovastatin exerted block effect by interacting with inactivated channel, because pure Kv1.3 open channel blockers staurosporine and fluoxetine have no effect on the steady-state inactivated . We calculated the K i value for Lovastatin binding to the inactivated Kv1.3 channel, and compared this value with the IC 50 of Lovastatin on peak or pulse end Kv1.3 current. The K i value reduced by 40-and 7-fold relatively, which suggested that Lovastatin is much more potent on channel inactivation. This characteristic is very similar to FK-506 28 . There are not many reports studying the binding sites of Statins and ion channels. Our results of the competitive experiments with well-defined inner-pore blockers TEA and verapamil suggested that Lovastatin interacted with the inner pore of Kv1.3. We further investigated the effects of Lovastatin on the mutant channels (H399A and V417A) and found that V417A significantly reduced the blockade effects of Lovastatin. This particular position has been described previously to be involved in the binding of verapamil to Kv1.3 41 . However, the precise binding sites of Lovastatin require further study. Kv1.3 is the dominantly expressed K + channel in human T cells, which provides driving force for Ca 2+ influx by maintaining the resting membrane potential. Blocking Kv1.3 channel can depolarize the membrane potential 42 , decrease Ca 2+ influx and then inhibit the T cell activation 18 . Along with Kv1.3 channel, T cells also express K Ca channel, which assist to maintain the membrane potential 17, 43, 44 . In our study, acute application with Lovastatin significantly inhibited the Ca 2+ influx into Jurkat cells. But Lovastatin at 30 μ M apparently blocked Kv1.3 channel without affecting the K Ca currents. Thus, the effect of Lovastatin on Ca 2+ influx may attribute to the blocking of Kv1.3 instead of K Ca channels. However, the direct blockade of Lovastatin on CRAC channels (the channel for Ca 2+ entry) requires further investigation. Ca 2+ influx can activate the Ca 2+ -related transcription factors, and ultimately lead to cytokine release and T cell proliferation as well 18 . We also observed that Lovastatin down-regulated the Ca
2+
-related NFAT1 and NF-κ B p65/50 activities. In a previous study, Lovastatin inhibited the IL-2 secretion of human PBTCs in a concentration-dependent manner 45 . Similarly, we found that Lovastatin apparently decreased the IL-2 production of Jurkat cells and PBTCs proliferation. The knockdown of Kv1.3 channel significantly attenuated the block effect of Lovastatin on IL-2 secretion, which indicated that Lovastatin exert anti-inflammatory action by blocking Kv1.3 channnel. Many previous studies have proved that Lovastatin can down-regulate the serum inflammation mediators IL-6, TNF-α , and CRP 46, 47 . Lovastatin also performs immunomodulatory function in T cell-mediated autoimmune diseases by inhibiting theisoprenoid and Mevalonate pathway 3 . For example, Lovastatin alleviated the autoimmune retinal disease by inhibiting the isoprenoid pyrophosphate synthesis and activation of GTPase 15 . In experimental autoimmune phalomyelitis model, Lovastatin exerted therapy action through altering the Th1/Th2 cytokines ratio 8 . In a rat model for Guillain-Barre´ syndrome, Lovastatin attenuated the nerve damage by decreasing the proliferation and migration of autoimmune lymphocytes, which can be neutralized by Mevalonate injection 48 . But in our study, we applied Mevalonate in the presence of Lovastatin, and found that the inhibitory action of Lovastatin on IL-2 was only partly neutralized. Therefore, besides the classical Mevalonate pathway, Lovastatin can perform immunodulation function by blocking Kv1.3 channel. In T cell-mediated autoimmune diseases, Lovastatin may possess important therapeutic meanings by blocking Kv1.3 channel and inhibiting the pathogenic action of T EM cells without affecting the physiological immune reactions (which is mediated by the up-regulation of K Ca channels 49 ). In summary, our study proved that HMG-CoA inhibitor Lovastatin can block Kv1.3 channel, decrease Ca 2+ influx and Ca 2+ -activated transcriptional factors, and finally inhibit the proliferation, IL-2 secretion of T cells, which is probably a new mechanism for its immunomodulatory effect. Kv1.3 blocker Lovastatin might play important therapeutic roles in T cell-mediated immune diseases.
Methods
Ethics statement. Our study protocol of the healthy volunteers' blood samples was conducted according to the Declaration of Helsinki and Tokyo for humans. The protocol was also approved by the Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology (Approval reference number: IORG0003571). Healthy volunteers were all provided with written informed consent for the collection of blood and the subsequent T cell isolation and analysis.
Chemicals. Lovastatin was a gift from Prof. Huang (Xiamen, China). Phytohematogglutinin (PHA) and phorbol ester (PMA) were obtained from Sigma-Aldrich (St Louis, MO, USA). Thapsigargin (TG) was obtained from Alomone Laboratories (Jerusalem, Israel), and fluo-4 AM was purchased from Invitrogen (Carlsbad,CA, USA). RPMI 1640, fetal bovine serum, and penicillin/streptomycin were all from Gibco (Grand Island, NY, USA). Lovastatin was dissolved in DMSO at 100 mM stock concentration. All aliquoted stock was kept light protected at − 20 °C. During all experiments, the final concentration of DMSO in cell culture medium were no more than 0.1%, and the control with corresponding DMSO was used to discard the possible non-specific effects.
Cell preparation. The human Jurkat T cell-line was obtained from the China Center for Type Culture Collection (Wuhan, China). Mononuclear cells were separated using the density Ficoll gradients from the whole blood of healthy volunteers. Then, CD4
+ T cells were purified using a CD4 + T Cell Isolation Kit (Miltenyi Biotec, Bergisch-Gladbach, Germany). All the cells mentioned above were cultured in RPMI1640 supplemented with 10% heat-inactivated FBS, 10 mM HEPES, 2 mM L-glutamate and 1% penicillin/streptomycin at 37 °C in humidified atmosphere (5% CO 2 ).
Human embryonic kidney 293 (HEK 293) cells were cultured in the same condition as described above. HEK 293 cells were transiently transfected with appropriate cDNA plasmids using Lipofectamine LTX and PLUS (Invitrogen) method as described previously 50 . The cDNA encoding human Kv1.2 (from Prof. Yingliang Wu, Wuhan University, Wuhan, China), human Kv1.3 (generously provided by Dr. Garcia Maria, Merck & Co. Inc., West Point, PA, USA) and human Kv1.5 (from Prof. Guirong Li, Hongkong University, Hongkong, China) were subcloned into the vector of pIRES2-EGFP (Clontech, USA). Point mutations were introduced into the Kv1.3 channel (H399A, V417A) and subcloned into the pRc/CMV plasmid expression vector, which were kindly given by Prof. Yingliang Wu, Wuhan University, Wuhan, China. All plasmids were verified by DNA sequencing before expression. Currents were recorded 48 h after transfection.
Electric recordings and analysis. The Jurkat T cell-line, human PBTCs and HEK 293 cells were used for the patch-clamp electrophysiological recordings. All studies were performed in the whole-cell recording mode at room temperature as described in our previous studies 19, 20, 31 . The external solution contained (in mM): 137 NaCl, 4 KCl, 1 MgCl 2 , 1.8 CaCl 2 , 10 Glucose and 10 HEPES, adjusted to pH 7.4 with NaOH. The pipette solution for Kv1.3 channel currents recording (in mM) was 130 KCl, 1 MgCl 2 , 5 EGTA, 5 Mg-ATP, and 10 HEPES, adjusted to pH 7.2 with KOH. For K Ca recording, the pipette solution contained (in mM) 130 potassium aspartate, 10 EGTA, 8.55 CaCl 2 , 2.08 MgCl 2 , and 10 HEPES, adjusted to pH 7.2 with KOH. In some studies of K Ca , the external solution was replaced by the K + Ringer solution, in which all NaCl was replaced by KCl. The depolarization pulse protocol was described in the corresponding results and Figure Legends . The pClamp9.0 and Origin 8.5 software were used for the data acquisition and analysis. The equations used were the same as previously described 19 to obtain the IC 50 (drug concentration required for the 50% inhibition of the channel currents), Hill coefficient, inhibition%, half-maximum voltage (V 1/2 ) and slope factor (k) for activation or inactivation, and the reciprocal of the slope (K i ).
Quantitative real-time PCR. Jurkat T cells were seeded and incubated with 10, 30, 100 μ M Lovastatin for 24 h, The control group was treated with the corresponding amount of DMSO. Total RNA was isolated from Jurkat T cells using trizol reagent (Invitrogen, CA, USA). cDNA synthesis was performed with RT reagent Kit (Takara Bio., Shiga, Japan). The primers used for the Kv1.3 and GAPDH are as previously described 31 . The real-time PCR Kit (Takara) was used and the reactions were performed in Stepone ABI system. GAPDH was applied as an internal reference. In all experiments, negative controls were included in the absence of the reverse transcriptase. The relative expression quantity 2 −ΔΔCt value was calculated to reflect the differences among the groups. analyzed as previously described 19 . The primary antibodies against Kv1.3 (1:500, Alomone), NFAT1 (1:500, Genetex, Irvine, CA, USA), phospho-NF-κ B p65/p50 (1:1000, Cell Signaling Technology, MA, USA) and GAPDH (1:2000, Abcam, MA, USA) were applied in our experiments. GAPDH was used as the internal reference. The protein expression levels were measured by enhanced chemiluminescence and analyzed with Image Lab Software. Knockdown of Kv1.3 expression with small interfering RNA. The Jurkat T cell-lines stably transfected with lentivirus-delivered negative control (NC)-siRNA or Kv1.3-siRNA were provided by Genepharma Company (Shanghai, China). Western blotting has been performed to confirm the efficiency of siRNA knockdown 31 . The cell-lines were treated as described above and the supernatants were collected for IL-2 production measurement.
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